vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $39.9M, roughly 1.2× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -42.0%, a 47.6% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -6.4%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

BCYC vs HHS — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.2× larger
BCYC
$48.0M
$39.9M
HHS
Growing faster (revenue YoY)
BCYC
BCYC
+1208.7% gap
BCYC
1193.3%
-15.4%
HHS
Higher net margin
HHS
HHS
47.6% more per $
HHS
5.5%
-42.0%
BCYC
More free cash flow
HHS
HHS
$19.2M more FCF
HHS
$-686.0K
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
HHS
HHS
Revenue
$48.0M
$39.9M
Net Profit
$-20.2M
$2.2M
Gross Margin
Operating Margin
-51.5%
-0.3%
Net Margin
-42.0%
5.5%
Revenue YoY
1193.3%
-15.4%
Net Profit YoY
61.1%
EPS (diluted)
$-0.29
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
HHS
HHS
Q4 25
$48.0M
$39.9M
Q3 25
$11.7M
$39.5M
Q2 25
$2.9M
$38.6M
Q1 25
$10.0M
$41.6M
Q4 24
$3.7M
$47.1M
Q3 24
$2.7M
$47.6M
Q2 24
$9.4M
$45.0M
Q1 24
$19.5M
$45.4M
Net Profit
BCYC
BCYC
HHS
HHS
Q4 25
$-20.2M
$2.2M
Q3 25
$-59.1M
$-2.3M
Q2 25
$-79.0M
$-335.0K
Q1 25
$-60.8M
$-392.0K
Q4 24
Q3 24
$-50.8M
$142.0K
Q2 24
$-39.8M
$-27.8M
Q1 24
$-26.6M
$-171.0K
Operating Margin
BCYC
BCYC
HHS
HHS
Q4 25
-51.5%
-0.3%
Q3 25
-558.6%
1.3%
Q2 25
-2965.8%
0.1%
Q1 25
-703.7%
-0.1%
Q4 24
-3.3%
Q3 24
-2385.9%
4.0%
Q2 24
-498.3%
3.0%
Q1 24
-162.4%
0.8%
Net Margin
BCYC
BCYC
HHS
HHS
Q4 25
-42.0%
5.5%
Q3 25
-503.7%
-5.8%
Q2 25
-2703.8%
-0.9%
Q1 25
-608.9%
-0.9%
Q4 24
Q3 24
-1898.4%
0.3%
Q2 24
-425.3%
-61.8%
Q1 24
-136.0%
-0.4%
EPS (diluted)
BCYC
BCYC
HHS
HHS
Q4 25
$-0.29
$0.30
Q3 25
$-0.85
$-0.31
Q2 25
$-1.14
$-0.05
Q1 25
$-0.88
$-0.05
Q4 24
$-0.31
Q3 24
$-0.74
$0.02
Q2 24
$-0.77
$-3.84
Q1 24
$-0.62
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
HHS
HHS
Cash + ST InvestmentsLiquidity on hand
$628.1M
$5.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$20.5M
Total Assets
$717.6M
$91.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
HHS
HHS
Q4 25
$628.1M
$5.6M
Q3 25
$648.3M
$6.5M
Q2 25
$721.5M
$4.8M
Q1 25
$793.0M
$9.0M
Q4 24
$879.5M
$9.8M
Q3 24
$890.9M
$5.9M
Q2 24
$961.4M
$11.0M
Q1 24
$457.0M
$11.5M
Total Debt
BCYC
BCYC
HHS
HHS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
HHS
HHS
Q4 25
$610.0M
$20.5M
Q3 25
$618.5M
$19.9M
Q2 25
$668.9M
$22.2M
Q1 25
$740.3M
$21.4M
Q4 24
$793.1M
$21.7M
Q3 24
$831.0M
$21.0M
Q2 24
$873.8M
$20.6M
Q1 24
$356.0M
$20.0M
Total Assets
BCYC
BCYC
HHS
HHS
Q4 25
$717.6M
$91.8M
Q3 25
$764.0M
$92.7M
Q2 25
$832.2M
$95.0M
Q1 25
$883.9M
$100.6M
Q4 24
$956.9M
$101.8M
Q3 24
$996.7M
$108.1M
Q2 24
$1.1B
$109.7M
Q1 24
$547.1M
$113.4M
Debt / Equity
BCYC
BCYC
HHS
HHS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
HHS
HHS
Operating Cash FlowLast quarter
$-19.3M
$737.0K
Free Cash FlowOCF − Capex
$-19.9M
$-686.0K
FCF MarginFCF / Revenue
-41.5%
-1.7%
Capex IntensityCapex / Revenue
1.2%
3.6%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$-4.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
HHS
HHS
Q4 25
$-19.3M
$737.0K
Q3 25
$-71.2M
$3.2M
Q2 25
$-72.8M
$-4.8M
Q1 25
$-86.4M
$-818.0K
Q4 24
$-164.7M
$4.0M
Q3 24
$-39.8M
$-2.9M
Q2 24
$-44.6M
$1.6M
Q1 24
$-70.9M
$-5.7M
Free Cash Flow
BCYC
BCYC
HHS
HHS
Q4 25
$-19.9M
$-686.0K
Q3 25
$-71.8M
$2.2M
Q2 25
$-73.3M
$-5.1M
Q1 25
$-87.0M
$-923.0K
Q4 24
$-166.0M
$3.4M
Q3 24
$-40.3M
$-4.9M
Q2 24
$-45.0M
$926.0K
Q1 24
$-70.9M
$-6.2M
FCF Margin
BCYC
BCYC
HHS
HHS
Q4 25
-41.5%
-1.7%
Q3 25
-612.3%
5.5%
Q2 25
-2509.7%
-13.1%
Q1 25
-871.7%
-2.2%
Q4 24
-4475.7%
7.3%
Q3 24
-1504.7%
-10.2%
Q2 24
-481.2%
2.1%
Q1 24
-362.9%
-13.7%
Capex Intensity
BCYC
BCYC
HHS
HHS
Q4 25
1.2%
3.6%
Q3 25
5.7%
2.5%
Q2 25
17.1%
0.6%
Q1 25
6.1%
0.3%
Q4 24
33.3%
1.3%
Q3 24
16.3%
4.0%
Q2 24
4.5%
1.5%
Q1 24
0.1%
1.2%
Cash Conversion
BCYC
BCYC
HHS
HHS
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-20.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

Related Comparisons